Improved Survival Trends in Platinum-Resistant Patients with Advanced Ovarian, Fallopian or Peritoneal Cancer Treated with First-Line Paclitaxel/Platinum Chemotherapy: The Impact of Novel Agents

Publisher： Karger

E-ISSN： 1423-0232|84|3|158-165

ISSN： 0030-2414

Source： Oncology, Vol.84, Iss.3, 2012-12, pp. : 158-165

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Dose Finding Study for Combination Treatment with Topotecan and Gemcitabine of Patients with Recurrent Ovarian Cancer after Failure of First-Line Chemotherapy with Paclitaxel and Platinum

By  

Oncology Research and Treatment, Vol. 27, Iss. 1, 2004-03 ,pp. : 58-64

Karger

Access to resources Recommend Favorite

Gemcitabine Combined with Oxaliplatin (GEMOX) as Second-Line Chemotherapy in Patients with Advanced Ovarian Cancer Refractory or Resistant to Platinum and Taxane

By  

Oncology, Vol. 67, Iss. 5-6, 2005-02 ,pp. : 376-381

Karger

Access to resources Recommend Favorite

A Phase I Study of Paclitaxel and Epirubicin, without and with Filgrastim, for the Treatment of Platinum-Resistant Advanced Ovarian Cancer

By  

Oncology, Vol. 56, Iss. 4, 1999-05 ,pp. : 267-273

Karger

Access to resources Recommend Favorite

Second-Line Treatment with Intravenous Gemcitabine and Oral Etoposide in Platinum-Resistant Advanced Ovarian Cancer Patients: Results of a Phase II Study

By  

Oncology, Vol. 80, Iss. 3-4, 2011-07 ,pp. : 238-246

Karger

Access to resources Recommend Favorite

Gemcitabine plus Paclitaxel as First-Line Chemotherapy for Patients with Advanced Breast Cancer

By  

Oncology, Vol. 66, Iss. 1, 2004-03 ,pp. : 18-23

Karger

Access to resources Recommend Favorite